PUBLICATIONS

Bo-Hyun Choi, Vipin Rawat, Jenny Högström, Philippa A. Burns, Kelly O. Conger, Mete Emir Ozgurses, Jaymin M. Patel, Tejas S. Mehta, Angelica Warren, Laura M. Selfors, Taru Muranen, Jonathan L. Coloff. Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. Cell Reports, Volume 38, Issue 3, 2022,110278,ISSN 2211-1247,https://doi.org/10.1016/j.celrep.2021.110278.

Nina Kozlova, Joseph E Grossman, Marcin P Iwanicki and Taru Muranen. The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stoma-Rich Cancers. Trends in Pharmacology Sci. (2020). Mar 41 (3):183-198. PMID: 32014341.

Sadaf Farsinejad, Thomas Cattabiani, Taru Muranen and Marcin Iwanicki. Ovarian Cancer Dissemination — A Cell Biologist’s Perspective. (2019). Cancers (Basel). Dec6;11(12):1957. PMID:31817625.

Taru Muranen, Marcin P. Iwanicki, Natasha L. Curry, Julie Hwang, Cory D. DuBois, Jonathan L. Coloff, Daniel S. Hitchcock, Clary B. Clash, Joan S. Brugge and Nada Y. Kalaany. Starved Epithelial Cells Uptake Extracellular Matrix for Survival. (2017). Nature Communications. Jan 10. http://rdcu.be/oqQ6

Taru Muranen, Laura M. Selfors, Julie Hwang, Lisa L. Gallegos, Jonathan L. Coloff, Carson C. Thoreen, Seong A. Kang, David M. Sabatini, Gordon B. Mills and Joan S. Brugge. ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition Via Regulation of MYC and YAP. (2016). Cancer Research. Dec 15;76(24):7168-7180. 

Marcin P. Iwanicki, Hsing-Yu Chen, Claudia Iavarone, Ioannis K. Zervantonakis, Taru Muranen,  Marián Noval, Tan A. Ince, Ronny Drapkin and Joan S. Brugge. (2016) Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. Journal of Clinical Investigation Insights. 2016 Jul 7;1(10).

Muranen T, Meric-Bernstam F, Mills GB. Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. (2014). Preview. Cancer Cell. 21(2):227-239.

Elkabets M*, Vora S*, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos A.B, Rodon J, Ibrahim Y.H, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman J.A, Scaltriti M, Baselga J. (2013) mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA- Mutant Breast Cancer. Sci. Transl. Med. 5, 196ra99. * equal contributionMuranen T. Cell-cell and cell-matrix interaction. (2013). Mol Biol Cell. Mar;24(6):671.  

Laulajainen M, Melikova M, Muranen T, Carpén O and Grönholm M. (2012)Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity.J Cell Mol Med. 16:2165-75. 

Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB and Brugge JS. (2012).Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 21:227-39.

Iwanicki M.P, Davidowitz R.A, Ng M.R, Besser A, Muranen T, Merritt M, Danuser G, Ince T, and Brugge J.S. (2011).Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discovery. 1:144-157. 

Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG. (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics. 43(9):869-74. 

Laulajainen M, Muranen T, Nyman TA, Carpén O and Grönholm M. (2011)Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.Neoplasia. 7:643-52. 

Laulajainen M*, Muranen T*, Carpén O and Grönholm M. (2008) Protein kinase A mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects actin cytoskeleton. Oncogene. 27(23):3233-43. *equal contribution.

Muranen T, Grönholm M, Lampin A, Lallemand D, Zhao F, Giovannini M and Carpén O. (2007).The tumor suppressor merlin interacts with microtubules in a regulated manner and modulates the microtubule cytoskeleton of primary mouse Schwann cells. Hum Mol Genet. 16:1742-1751.

Grönholm M*, Muranen T*, Toby GG, Utermark T, Hanemann CO, Golemis EA, and Carpén O. (2006).A functional association between merlin and HEI10, a cell cycle regulator. Oncogene. 25:4389-98. *equal contribution.

Muranen T*, Grönholm M*, Renkema HG, and Carpén O. (2005).Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin.Oncogene. 24:1150-58. *equal contribution.